Form 4: Immunovant CTO Sells Shares for Tax Obligations

Immunovant's Chief Technology Officer, Jay S. Stout, sold 1,203 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Jay S. Stout, Chief Technology Officer of Immunovant, Inc. (IMVT), reported transactions involving the company's common stock.
• On January 7, 2026, Stout sold a total of 1,203 shares of common stock.
• The sales were executed at weighted average prices of $26.51 (for 1,148 shares, ranging from $25.90 to $26.89) and $26.92 (for 55 shares, ranging from $26.91 to $26.94).
• These sales were non-discretionary "sell to cover" transactions, mandated by the issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units (RSUs).
• Specifically, 3,436 RSUs, granted on April 2, 2024, vested on January 2, 2026.
• Following these transactions, Stout beneficially owns 199,611 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary "sell to cover" event for tax withholding purposes related to RSU vesting. It does not reflect a discretionary decision by the officer regarding the company's prospects and is therefore neutral in sentiment.

Positives

• The transaction is a routine, non-discretionary event related to executive compensation, indicating a standard process for RSU vesting and tax obligations.

Negatives

• No direct negatives are indicated by this routine, non-discretionary transaction.

Future Outlook

Not applicable; this Form 4 reports past transactions and does not provide forward-looking statements or guidance.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs.
• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This transaction is a standard practice in executive compensation within the biotechnology and pharmaceutical industries, where equity awards like RSUs are common. "Sell to cover" transactions are a routine mechanism for executives to meet tax liabilities upon the vesting of such awards, rather than indicating a discretionary decision to sell shares based on company performance or outlook.

Comparison to Industry Standards

• "Sell to cover" transactions are a widely accepted and common method for executives across various industries, including biotech, to manage tax obligations arising from equity compensation.
• This practice aligns with typical corporate governance and compensation structures seen in publicly traded companies, such as those in the S&P 500, where executives often receive a significant portion of their compensation in the form of restricted stock or options.
• No specific comparable companies or projects are mentioned in the filing, but the mechanism itself is standard.

Stakeholder Impact

• Shareholders: Minimal impact, as the sale is routine and non-discretionary, not signaling a change in management's confidence.
• Employees: No direct impact mentioned.
• Customers, Suppliers, Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by the Chief Technology Officer to cover tax withholding obligations upon the vesting of restricted stock units. Such "sell to cover" transactions are a standard part of executive compensation and do not typically indicate a change in the officer's view of the company's future prospects or fundamental value. Therefore, this filing alone does not provide a basis for a change in investment recommendation; a "hold" stance is appropriate as it's a neutral event.

Keywords

Immunovant, IMVT, Form 4, insider transaction, stock sale, RSU vesting, tax withholding, Chief Technology Officer, equity compensation